UniQure surges after encouraging trial results for Huntington’s treatment

UniQure rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years.

The treatment, AMT-130, is a one-time treatment for Huntington’s, a genetic brain disease that degrades cognitive function and muscle control. There is currently no cure for the disease.

UniQure said it plans to submit the treatment for approval to the Food and Drug Administration in the first quarter of 2026, meaning it could become available to patients later that year. The company currently makes nearly all of its revenue from gene therapies that treat hemophilia.

More Markets

See all Markets

Netflix sinks on lower-than-expected earnings forecast

Netflix’s report dropped on the same day it officially went all-cash in its bid for Warner Bros. Discovery.

Max Knoblauch15h

United Airlines rallies after Q4 earnings and Q1 profit guidance top estimates

Shares of United Airlines are rising after the bell on Tuesday, following the release of the carrier’s fourth-quarter and full-year earnings report.

United posted adjusted earnings per share of $3.10 in Q4, above the $2.92 per share expected by Wall Street analysts polled by Bloomberg. Sales of $15.4 billion were roughly in line with the consensus estimate.

The airline also:

Forecast full-year earnings per share between $12 and $14, bracketing Wall Street’s call for $13.04. For Q1, management sees EPS between $1.00 and $1.50, the midpoint of which is above the $1.16 expected by Wall Street.
Booked $13.93 billion in passenger revenue on the quarter, up nearly 5% year over year.

“Strong revenue momentum has continued into 2026,” according the company’s press release. “The week ending January 4th was the highest flown revenue week in United history, and the week ending January 11th was the highest ticketing week and the highest week for business sales in United history.”

UAL’s premium ticket revenue climbed 9% compared to a 7% increase in basic economy revenue. The “K-shaped economy” has become increasingly visible in travel trends at major US airlines. Last week, Delta’s revenue from first-class and business passengers eclipsed its main cabin revenue for the first time.

Luke Kawa

16h

Traders will soon have 3x as many opportunities to punt short-term options on the biggest US stocks

And that means 3x the opportunities for gamma/pin risk in the largest US stocks (and the biggest bitcoin ETF).

Craps, Roulette and Sports Betting Debuts at Seminole Hard Rock Hotel & Casino Hollywood

President Trump Delivers An Announcement From The Oval Office

Pharma largely unfazed as Greenland tariffs roil markets

Drugmakers, which have spent the past six months reaching tariff deals with Trump, seem to expect some immunity from a new batch of tariffs on European countries.

J. Edward Moreno18h

Luke Kawa20h

POET Technologies nears multiyear high on strong call demand after flagship product wins award

POET Technologies is surging on heavy volumes and high call demand after announcing that it won a Product Innovation Award at China’s Infostone awards.

The honor went to the optical communications company’s flagship product, the Teralight, which uses light to move data between chips.

“Unveiled less than a year ago at the 2025 OFC Conference, POET Teralight has driven commercial interest in the Company because of its highly integrated design and complete optical system-on-chip architecture that simplifies module development,” per the press release.

This award may be the latest excuse to buy the stock, which is up over 40% year to date.

Call activity is elevated, with nearly 37,000 having changed hands as of 10:55 a.m. ET, well above the 20-day average of 28,030 for a full session. Shares are approaching their multi-year high of $9.41.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.